Core Points - The company reported a decrease in revenue and a significant net loss for the first half of 2025 compared to the same period in the previous year [1][3] - The company plans not to distribute cash dividends or issue bonus shares [1] Financial Performance - Revenue for the reporting period was approximately CNY 2.16 billion, down 3.06% from CNY 2.23 billion in the previous year [1] - The net profit attributable to shareholders was a loss of approximately CNY 7.61 million, a decline of 162.95% from a profit of CNY 12.10 million in the same period last year [1] - The net profit after deducting non-recurring gains and losses was a loss of approximately CNY 8.32 million, down 198.14% from a profit of CNY 8.48 million [1] - The net cash flow from operating activities was a negative CNY 7.28 million, a decrease of 315.44% from a positive CNY 3.38 million [1] - Basic and diluted earnings per share were both negative CNY 0.08, compared to positive CNY 0.13 in the previous year [1] Assets and Equity - Total assets at the end of the reporting period were approximately CNY 1.75 billion, an increase of 1.91% from CNY 1.72 billion at the end of the previous year [3] - Net assets attributable to shareholders were approximately CNY 832.35 million, down 2.02% from CNY 849.54 million at the end of the previous year [3] Shareholder Information - The company had a total of 15,032 common shareholders at the end of the reporting period [3] - Li Yanfei is the controlling shareholder and actual controller of the company, holding 36.97% of the shares [4]
药易购: 2025年半年度报告摘要